<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00557245</url>
  </required_header>
  <id_info>
    <org_study_id>32528-A</org_study_id>
    <secondary_id>IND 75,365;</secondary_id>
    <secondary_id>07-7454-A-01</secondary_id>
    <nct_id>NCT00557245</nct_id>
  </id_info>
  <brief_title>Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples</brief_title>
  <acronym>Partners PrEP</acronym>
  <official_title>Parallel Comparison of Tenofovir and Emtricitabine/Tenofovir Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, blinded, placebo-controlled trial to demonstrate if pre-exposure prophylaxis
      decreases HIV-1 acquisition among HIV-1 uninfected individuals within HIV-1 discordant
      couples.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HIV-1 uninfected individuals within HIV-1 discordant partnerships are at high-risk for
      HIV-acquisition. The majority of HIV-1 transmissions to adults in Africa occur within stable,
      HIV-1 discordant couples.

      Pre-exposure chemoprophylaxis, in which an HIV-1 uninfected individual at high risk for
      contracting HIV-1 takes antiretroviral medications to maintain blood and genital drug levels
      sufficient to prevent HIV-1 acquisition, has been proposed as a potential HIV-1 prevention
      strategy.

      This study was a randomized, blinded, placebo-controlled trial to demonstrate if pre-exposure
      prophylaxis decreases HIV-1 acquisition among HIV-1 uninfected individuals within HIV-1
      discordant couples. The HIV-1 uninfected partner was randomized in a 1:1:1 ratio to one of
      three arms: once daily Tenofovir Disoproxil Fumarate (TDF), Emtricitabine/Tenofovir
      Disoproxil Fumarate (FTC/TDF) or Placebo.

      Couples were followed up to 36 months; the HIV uninfected partner attended monthly visits and
      the HIV infected partner quarterly visits. All participants received a comprehensive package
      of HIV prevention services including individual and couples counseling, free condoms, and
      male circumcision referrals.

      Participants who seroconverted during follow-up stopped the study drug but continued with
      follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of HIV-1 Seroconversion Among HIV-1 Uninfected Participants</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>The efficacy of once daily PrEP in preventing HIV-1 acquisition among uninfected heterosexuals in HIV-1 discordant partnerships, measured by calculating the HIV incidence per 100 person-years in each of three arms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Safety of daily TDF or FTC/TDF among HIV-1 uninfected individuals randomized to TDF or FTC/TDF compared to those randomized to placebo measured as the number of participants with Serious Adverse Events (SAEs) during follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Study Drug Adherence: Total Number of Study Drug Doses Taken of the Total Dispensed Doses.</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Adherence to study medication as assessed by pill count at follow-up visits. We assessed the total number of doses taken of the total dispensed doses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study Drug Adherence: Self-reported Missed Doses of Study Drug</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Adherence to study drug measured as the percentage of visits when participants reported missing 1) any dose of study drug in the prior month and 2) 2 or more consecutive doses of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroconverters With an HIV-1 Mutation Conferring Resistance to TDF or FTC</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>HIV-1 resistance as measured by the number of seroconverters who had an HIV-1 reverse transcriptase mutation (K65R, K70E, M184I, or M184V) conferring resistance to TDF or FTC. These mutation types were pre-defined. Plasma samples for resistance testing were collected at the visit seroconversion was first detected and again at a visit within 1 month of seroconversion. Mutations detected at either of those visits are reported.
Both seroconverters found to have a resistance mutation had been HIV infected at enrollment (TDF arm: n=1; FTC-TDF arm: n=1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Sexually Transmitted Infection (STI) During Follow-up</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Prevalence of STIs measured as the number of participants with a positive test result for N. gonorrhoeae, C. trachomatis, or T. vaginalis during follow-up. Participants were tested for STIs at annual follow-up visits and at intervening visits at which the participant presented with symptoms of an STI. Assessment for symptomatic sexually transmitted infections was conducted quarterly.
N. gonorrhoeae and C. trachomatis testing were by APTIMA Combo 2 (Gen-Probe) or COBAS Amplicor (Roche Diagnostics). T. vaginalis testing was by APTIMA TV TMA (Gen-Probe) or In Pouch TV (Biomed Diagnostics).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of Unprotected Sex During Follow-up</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Sexual risk behavior of participants, measured as the percentage of visits when participants reported having unprotected sex during follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Congenital Abnormalities Among Infants Born to Female Participants Taking Study Drug.</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Infant outcomes measured as the number of live-born infants born to female participants taking study drug that had any congenital anomalies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length Among Infants Born to Female Participants Taking Study Drug</measure>
    <time_frame>up to 12 months</time_frame>
    <description>The slope of the linear model of the growth of infants (length) during the entirety of follow-up. The length of the infant was measured as a z-score, in terms of standard deviations from the age and gender specific median using the World Health Organization growth curve, accounting for skewness. The slope, representing the change over time of the z-score, was calculated using all available z-scores over 12 months and regressing against study month.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight Among Infants Born to Female Participants Taking Study Drug</measure>
    <time_frame>up to 12 months</time_frame>
    <description>The slope of the linear model of the growth of infants (weight) during the entirety of follow-up. The weight of the infant was measured as a z-score, in terms of standard deviations from the age and gender specific median using the World Health Organization growth curve, accounting for skewness. The slope, representing the change over time of the z-score, was calculated using all available z-scores over 12 months and regressing against study month.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Head Circumference Among Infants Born to Female Participants Taking Study Drug</measure>
    <time_frame>up to 12 months</time_frame>
    <description>The slope of the linear model of the growth of infants (head circumference) during the entirety of follow-up. The head circumference of the infant was measured as a z-score, in terms of standard deviations from the age and gender specific median using the World Health Organization growth curve, accounting for skewness. The slope, representing the change over time of the z-score, was calculated using all available z-scores over 12 months and regressing against study month.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">4758</enrollment>
  <condition>HIV-1 Infections</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Tenofovir Disoproxil Fumarate (TDF)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TDF 300 mg tablet, once daily + Placebo FTC/TDF orally, once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FTC/TDF - 200 mg tablet, once daily + Placebo TDF orally, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo TDF + Placebo FTC/TDF orally, once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir Disoproxil Fumarate (TDF)</intervention_name>
    <description>TDF 300 mg tablet, once daily + Placebo FTC/TDF orally, once daily.</description>
    <arm_group_label>Tenofovir Disoproxil Fumarate (TDF)</arm_group_label>
    <other_name>Viread + Placebo Truvada</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)</intervention_name>
    <description>FTC/TDF - 200 mg tablet, once daily + Placebo TDF orally, once daily</description>
    <arm_group_label>Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)</arm_group_label>
    <other_name>Truvada + Placebo Viread</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo TDF &amp; Placebo FTC/TDF, 1 tablet each daily.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo + Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for HIV-1 uninfected partner:

          -  Partner within an HIV-1 discordant heterosexual relationship

          -  One partner meets study eligibility for HIV-1 uninfected study participant and the
             other partner meets study eligibility criteria for HIV-1 infected participant

          -  Plan to remain in the relationship for the duration of the study period

          -  Adequate renal, hepatic &amp; hematologic function

          -  Negative Hepatitis B surface antigen test

          -  Willing and able to provide written informed consent &amp; locator information

        Exclusion Criteria for HIV-1 uninfected partner:

          -  Current pregnancy, or planning to become pregnant during the study period

          -  Currently breastfeeding

          -  Concurrent enrollment in another HIV-1 vaccine or prevention trial

          -  Receiving ongoing antiretroviral therapy

          -  Repeated positive urine dipstick tests for glycosuria or proteinuria

          -  Active and serious infections

          -  History of pathological bone fractures not related to trauma

        Inclusion Criteria for HIV-1 infected partner:

          -  Partner within an HIV-1 discordant heterosexual relationship

          -  One partner meets study eligibility for HIV-1 uninfected study participant and the
             other partner meets study eligibility criteria for HIV-1 infected participant

          -  HIV-1 infected based on positive EIA

          -  No history of any clinical AIDS-defining diagnoses

          -  Plan to remain in the relationship for the duration of the study period

          -  Willing and able to provide written informed consent &amp; locator information

        Exclusion Criteria for HIV-1 infected partner:

          -  Current use of antiretroviral therapy

          -  Concurrent enrollment in another HIV-1 treatment trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Connie Celum,, MD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jared Baeten, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Moi University - Indiana University</name>
      <address>
        <city>Eldoret</city>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CMR, Kemri-UCSF</name>
      <address>
        <city>Kisumu</city>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kenyatta National Hospital/University of Nairobi</name>
      <address>
        <city>Nairobi</city>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Partners in Prevention - Thika</name>
      <address>
        <city>Thika</city>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kabwohe Clinical Research Center</name>
      <address>
        <city>Bushenyi</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infectious Diseases Institute</name>
      <address>
        <city>Jinja</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Partners House-Infectious Disease Institute Ltd</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The AIDS Support Organization (TASO)</name>
      <address>
        <city>Mbale</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The AIDS Support Organization - Tororo Field Station</name>
      <address>
        <city>Tororo</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kenya</country>
    <country>Uganda</country>
  </location_countries>
  <reference>
    <citation>Mujugira A, Baeten JM, Donnell D, Ndase P, Mugo NR, Barnes L, Campbell JD, Wangisi J, Tappero JW, Bukusi E, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH, Kiarie J, Farquhar C, John-Stewart G, Kidoguchi L, Panteleeff D, Krows M, Shah H, Revall J, Morrison S, Ondrejcek L, Ingram C, Coombs RW, Lingappa JR, Celum C; Partners PrEP Study Team. Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral pre-exposure prophylaxis for HIV-1 prevention. PLoS One. 2011;6(10):e25828. doi: 10.1371/journal.pone.0025828. Epub 2011 Oct 5.</citation>
    <PMID>21998703</PMID>
  </reference>
  <results_reference>
    <citation>Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH, Kiarie J, Farquhar C, John-Stewart G, Kakia A, Odoyo J, Mucunguzi A, Nakku-Joloba E, Twesigye R, Ngure K, Apaka C, Tamooh H, Gabona F, Mujugira A, Panteleeff D, Thomas KK, Kidoguchi L, Krows M, Revall J, Morrison S, Haugen H, Emmanuel-Ogier M, Ondrejcek L, Coombs RW, Frenkel L, Hendrix C, Bumpus NN, Bangsberg D, Haberer JE, Stevens WS, Lingappa JR, Celum C; Partners PrEP Study Team. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012 Aug 2;367(5):399-410. doi: 10.1056/NEJMoa1108524. Epub 2012 Jul 11.</citation>
    <PMID>22784037</PMID>
  </results_reference>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2007</study_first_submitted>
  <study_first_submitted_qc>November 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 12, 2007</study_first_posted>
  <results_first_submitted>October 30, 2014</results_first_submitted>
  <results_first_submitted_qc>November 20, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 27, 2014</results_first_posted>
  <last_update_submitted>November 20, 2014</last_update_submitted>
  <last_update_submitted_qc>November 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Connie Celum</investigator_full_name>
    <investigator_title>Protocol Chair</investigator_title>
  </responsible_party>
  <keyword>HIV infection</keyword>
  <keyword>HIV uninfected partners</keyword>
  <keyword>Double Blind</keyword>
  <keyword>Placebo</keyword>
  <keyword>Seroconversion</keyword>
  <keyword>TDF</keyword>
  <keyword>FTC TDF</keyword>
  <keyword>Safety</keyword>
  <keyword>HIV Seronegativity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tenofovir Disoproxil Fumarate (TDF)</title>
          <description>TDF 300 mg tablet, once daily + Placebo FTC/TDF orally, once daily.</description>
        </group>
        <group group_id="P2">
          <title>Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)</title>
          <description>FTC/TDF - 200 mg tablet, once daily + Placebo TDF orally, once daily</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo TDF &amp; Placebo FTC/TDF, 1 tablet each daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1589"/>
                <participants group_id="P2" count="1583"/>
                <participants group_id="P3" count="1586"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1577"/>
                <participants group_id="P2" count="1571"/>
                <participants group_id="P3" count="1574"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligible</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants, less those who were found to be ineligible (n=11)</population>
      <group_list>
        <group group_id="B1">
          <title>Tenofovir Disoproxil Fumarate (TDF)</title>
          <description>TDF 300 mg tablet, once daily + Placebo FTC/TDF orally, once daily.</description>
        </group>
        <group group_id="B2">
          <title>Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)</title>
          <description>FTC/TDF - 200 mg tablet, once daily + Placebo TDF orally, once daily</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo TDF &amp; Placebo FTC/TDF, 1 tablet each daily.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1584"/>
            <count group_id="B2" value="1579"/>
            <count group_id="B3" value="1584"/>
            <count group_id="B4" value="4747"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18-24 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="184"/>
                    <measurement group_id="B2" value="177"/>
                    <measurement group_id="B3" value="172"/>
                    <measurement group_id="B4" value="533"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25-34 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="721"/>
                    <measurement group_id="B2" value="690"/>
                    <measurement group_id="B3" value="688"/>
                    <measurement group_id="B4" value="2099"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>35-44 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="480"/>
                    <measurement group_id="B2" value="498"/>
                    <measurement group_id="B3" value="513"/>
                    <measurement group_id="B4" value="1491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 years and older</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="199"/>
                    <measurement group_id="B2" value="214"/>
                    <measurement group_id="B3" value="211"/>
                    <measurement group_id="B4" value="624"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="598"/>
                    <measurement group_id="B2" value="566"/>
                    <measurement group_id="B3" value="621"/>
                    <measurement group_id="B4" value="1785"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="986"/>
                    <measurement group_id="B2" value="1013"/>
                    <measurement group_id="B3" value="963"/>
                    <measurement group_id="B4" value="2962"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Kenya</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="700"/>
                    <measurement group_id="B2" value="698"/>
                    <measurement group_id="B3" value="697"/>
                    <measurement group_id="B4" value="2095"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uganda</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="884"/>
                    <measurement group_id="B2" value="881"/>
                    <measurement group_id="B3" value="887"/>
                    <measurement group_id="B4" value="2652"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Percentage of participants who had unprotected sex in the past month</title>
          <description>The percentage of participants who had any unprotected sex acts in the prior month.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of HIV-1 Seroconversion Among HIV-1 Uninfected Participants</title>
        <description>The efficacy of once daily PrEP in preventing HIV-1 acquisition among uninfected heterosexuals in HIV-1 discordant partnerships, measured by calculating the HIV incidence per 100 person-years in each of three arms.</description>
        <time_frame>Up to 36 months</time_frame>
        <population>All randomized participants, less those who were found to ineligible (n=11), less those found to be infected at enrollment (n=14), and less those who did not return for any follow-up (n=25).</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir Disoproxil Fumarate (TDF)</title>
            <description>TDF 300 mg tablet, once daily + Placebo FTC/TDF orally, once daily.</description>
          </group>
          <group group_id="O2">
            <title>Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)</title>
            <description>FTC/TDF - 200 mg tablet, once daily + Placebo TDF orally, once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo TDF &amp; Placebo FTC/TDF, 1 tablet each daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of HIV-1 Seroconversion Among HIV-1 Uninfected Participants</title>
          <description>The efficacy of once daily PrEP in preventing HIV-1 acquisition among uninfected heterosexuals in HIV-1 discordant partnerships, measured by calculating the HIV incidence per 100 person-years in each of three arms.</description>
          <population>All randomized participants, less those who were found to ineligible (n=11), less those found to be infected at enrollment (n=14), and less those who did not return for any follow-up (n=25).</population>
          <units>events per 100 person years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1572"/>
                <count group_id="O2" value="1568"/>
                <count group_id="O3" value="1568"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65" lower_limit="0.38" upper_limit="1.05"/>
                    <measurement group_id="O2" value="0.50" lower_limit="0.27" upper_limit="0.85"/>
                    <measurement group_id="O3" value="1.99" lower_limit="1.49" upper_limit="2.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>We used Cox regression stratified according to site, to estimate the relative rates of time to first positive HIV-1 serologic test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The a priori threshold was 0.05.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.19</ci_lower_limit>
            <ci_upper_limit>0.56</ci_upper_limit>
            <estimate_desc>Placebo arm is the reference group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>We used Cox regression stratified according to site, to estimate the relative rates of time to first positive HIV-1 serologic test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The a priori threshold was 0.05.</p_value_desc>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.13</ci_lower_limit>
            <ci_upper_limit>0.45</ci_upper_limit>
            <estimate_desc>Placebo arm is the reference group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Serious Adverse Events (SAEs)</title>
        <description>Safety of daily TDF or FTC/TDF among HIV-1 uninfected individuals randomized to TDF or FTC/TDF compared to those randomized to placebo measured as the number of participants with Serious Adverse Events (SAEs) during follow-up.</description>
        <time_frame>Up to 36 months</time_frame>
        <population>Randomized participants, less those found to be ineligible (n=11)</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir Disoproxil Fumarate (TDF)</title>
            <description>TDF 300 mg tablet, once daily + Placebo FTC/TDF orally, once daily.</description>
          </group>
          <group group_id="O2">
            <title>Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)</title>
            <description>FTC/TDF - 200 mg tablet, once daily + Placebo TDF orally, once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo TDF &amp; Placebo FTC/TDF, 1 tablet each daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Events (SAEs)</title>
          <description>Safety of daily TDF or FTC/TDF among HIV-1 uninfected individuals randomized to TDF or FTC/TDF compared to those randomized to placebo measured as the number of participants with Serious Adverse Events (SAEs) during follow-up.</description>
          <population>Randomized participants, less those found to be ineligible (n=11)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1584"/>
                <count group_id="O2" value="1579"/>
                <count group_id="O3" value="1584"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118"/>
                    <measurement group_id="O2" value="115"/>
                    <measurement group_id="O3" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.00</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.89</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study Drug Adherence: Total Number of Study Drug Doses Taken of the Total Dispensed Doses.</title>
        <description>Adherence to study medication as assessed by pill count at follow-up visits. We assessed the total number of doses taken of the total dispensed doses.</description>
        <time_frame>Up to 36 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir Disoproxil Fumarate (TDF)</title>
            <description>TDF 300 mg tablet, once daily + Placebo FTC/TDF orally, once daily.</description>
          </group>
          <group group_id="O2">
            <title>Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)</title>
            <description>FTC/TDF - 200 mg tablet, once daily + Placebo TDF orally, once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo TDF &amp; Placebo FTC/TDF, 1 tablet each daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Study Drug Adherence: Total Number of Study Drug Doses Taken of the Total Dispensed Doses.</title>
          <description>Adherence to study medication as assessed by pill count at follow-up visits. We assessed the total number of doses taken of the total dispensed doses.</description>
          <units>percentage of doses taken of dispensed</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1571"/>
                <count group_id="O2" value="1565"/>
                <count group_id="O3" value="1570"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="97"/>
                    <measurement group_id="O3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study Drug Adherence: Self-reported Missed Doses of Study Drug</title>
        <description>Adherence to study drug measured as the percentage of visits when participants reported missing 1) any dose of study drug in the prior month and 2) 2 or more consecutive doses of study drug.</description>
        <time_frame>Up to 36 months</time_frame>
        <population>Participants with self-reported adherence.</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir Disoproxil Fumarate (TDF)</title>
            <description>Tenofovir Disoproxil Fumarate (TDF): TDF 300 mg tablet, once daily + Placebo FTC/TDF orally, once daily.</description>
          </group>
          <group group_id="O2">
            <title>Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)</title>
            <description>Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF): FTC/TDF - 200 mg tablet, once daily + Placebo TDF orally, once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo TDF + Placebo FTC/TDF orally, once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Study Drug Adherence: Self-reported Missed Doses of Study Drug</title>
          <description>Adherence to study drug measured as the percentage of visits when participants reported missing 1) any dose of study drug in the prior month and 2) 2 or more consecutive doses of study drug.</description>
          <population>Participants with self-reported adherence.</population>
          <units>percentage of visits</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1549"/>
                <count group_id="O2" value="1552"/>
                <count group_id="O3" value="1551"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Missed any doses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missed 2+ consecutive doses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroconverters With an HIV-1 Mutation Conferring Resistance to TDF or FTC</title>
        <description>HIV-1 resistance as measured by the number of seroconverters who had an HIV-1 reverse transcriptase mutation (K65R, K70E, M184I, or M184V) conferring resistance to TDF or FTC. These mutation types were pre-defined. Plasma samples for resistance testing were collected at the visit seroconversion was first detected and again at a visit within 1 month of seroconversion. Mutations detected at either of those visits are reported.
Both seroconverters found to have a resistance mutation had been HIV infected at enrollment (TDF arm: n=1; FTC-TDF arm: n=1).</description>
        <time_frame>Up to 36 months</time_frame>
        <population>Participants who seroconverted during the Partners PrEP trial, including those who were retrospectively found to be HIV infected at enrollment (TDF arm: n=5; FTC-TDF arm: n=3; placebo arm: n=6). For 4 of 96 HIV-1 seroconverters (TDF arm: n=2; FTC-TDF arm: n=1; placebo arm: n=1) HIV-1 RNA was unable to be amplified for HIV-1 resistance testing.</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir Disoproxil Fumarate (TDF)</title>
            <description>TDF 300 mg tablet, once daily + Placebo FTC/TDF orally, once daily.</description>
          </group>
          <group group_id="O2">
            <title>Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)</title>
            <description>FTC/TDF - 200 mg tablet, once daily + Placebo TDF orally, once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo TDF &amp; Placebo FTC/TDF, 1 tablet each daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroconverters With an HIV-1 Mutation Conferring Resistance to TDF or FTC</title>
          <description>HIV-1 resistance as measured by the number of seroconverters who had an HIV-1 reverse transcriptase mutation (K65R, K70E, M184I, or M184V) conferring resistance to TDF or FTC. These mutation types were pre-defined. Plasma samples for resistance testing were collected at the visit seroconversion was first detected and again at a visit within 1 month of seroconversion. Mutations detected at either of those visits are reported.
Both seroconverters found to have a resistance mutation had been HIV infected at enrollment (TDF arm: n=1; FTC-TDF arm: n=1).</description>
          <population>Participants who seroconverted during the Partners PrEP trial, including those who were retrospectively found to be HIV infected at enrollment (TDF arm: n=5; FTC-TDF arm: n=3; placebo arm: n=6). For 4 of 96 HIV-1 seroconverters (TDF arm: n=2; FTC-TDF arm: n=1; placebo arm: n=1) HIV-1 RNA was unable to be amplified for HIV-1 resistance testing.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Sexually Transmitted Infection (STI) During Follow-up</title>
        <description>Prevalence of STIs measured as the number of participants with a positive test result for N. gonorrhoeae, C. trachomatis, or T. vaginalis during follow-up. Participants were tested for STIs at annual follow-up visits and at intervening visits at which the participant presented with symptoms of an STI. Assessment for symptomatic sexually transmitted infections was conducted quarterly.
N. gonorrhoeae and C. trachomatis testing were by APTIMA Combo 2 (Gen-Probe) or COBAS Amplicor (Roche Diagnostics). T. vaginalis testing was by APTIMA TV TMA (Gen-Probe) or In Pouch TV (Biomed Diagnostics).</description>
        <time_frame>Up to 36 months</time_frame>
        <population>Randomized participants, less those found to be ineligible (n=11)</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir Disoproxil Fumarate (TDF)</title>
            <description>TDF 300 mg tablet, once daily + Placebo FTC/TDF orally, once daily.</description>
          </group>
          <group group_id="O2">
            <title>Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)</title>
            <description>FTC/TDF - 200 mg tablet, once daily + Placebo TDF orally, once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo TDF &amp; Placebo FTC/TDF, 1 tablet each daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Sexually Transmitted Infection (STI) During Follow-up</title>
          <description>Prevalence of STIs measured as the number of participants with a positive test result for N. gonorrhoeae, C. trachomatis, or T. vaginalis during follow-up. Participants were tested for STIs at annual follow-up visits and at intervening visits at which the participant presented with symptoms of an STI. Assessment for symptomatic sexually transmitted infections was conducted quarterly.
N. gonorrhoeae and C. trachomatis testing were by APTIMA Combo 2 (Gen-Probe) or COBAS Amplicor (Roche Diagnostics). T. vaginalis testing was by APTIMA TV TMA (Gen-Probe) or In Pouch TV (Biomed Diagnostics).</description>
          <population>Randomized participants, less those found to be ineligible (n=11)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1584"/>
                <count group_id="O2" value="1579"/>
                <count group_id="O3" value="1584"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="76"/>
                    <measurement group_id="O3" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.24</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Generalized estimating equations, with logistic link and robust standard errors to adjust for individual correlation over time.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.49</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Generalized estimating equations, with logistic link and robust standard errors to adjust for individual correlation over time.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prevalence of Unprotected Sex During Follow-up</title>
        <description>Sexual risk behavior of participants, measured as the percentage of visits when participants reported having unprotected sex during follow-up.</description>
        <time_frame>Up to 36 months</time_frame>
        <population>All randomized participants, less those found to be ineligible (n=11).</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir Disoproxil Fumarate (TDF)</title>
            <description>Tenofovir Disoproxil Fumarate (TDF): TDF 300 mg tablet, once daily + Placebo FTC/TDF orally, once daily.</description>
          </group>
          <group group_id="O2">
            <title>Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)</title>
            <description>Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF): FTC/TDF - 200 mg tablet, once daily + Placebo TDF orally, once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo TDF + Placebo FTC/TDF orally, once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Prevalence of Unprotected Sex During Follow-up</title>
          <description>Sexual risk behavior of participants, measured as the percentage of visits when participants reported having unprotected sex during follow-up.</description>
          <population>All randomized participants, less those found to be ineligible (n=11).</population>
          <units>percentage of visits</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1584"/>
                <count group_id="O2" value="1579"/>
                <count group_id="O3" value="1584"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.32</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Generalized estimating equations, logistic link, with robust standard errors.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.66</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Generalized estimating equations, logistic link, with robust standard errors.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Congenital Abnormalities Among Infants Born to Female Participants Taking Study Drug.</title>
        <description>Infant outcomes measured as the number of live-born infants born to female participants taking study drug that had any congenital anomalies.</description>
        <time_frame>Up to 36 months</time_frame>
        <population>Randomized female participants, less those found to be ineligible (n=7)</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir Disoproxil Fumarate (TDF)</title>
            <description>TDF 300 mg tablet, once daily + Placebo FTC/TDF orally, once daily.</description>
          </group>
          <group group_id="O2">
            <title>Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)</title>
            <description>FTC/TDF - 200 mg tablet, once daily + Placebo TDF orally, once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo TDF &amp; Placebo FTC/TDF, 1 tablet each daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Congenital Abnormalities Among Infants Born to Female Participants Taking Study Drug.</title>
          <description>Infant outcomes measured as the number of live-born infants born to female participants taking study drug that had any congenital anomalies.</description>
          <population>Randomized female participants, less those found to be ineligible (n=7)</population>
          <units>Number of live-born infants</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="595"/>
                <count group_id="O2" value="565"/>
                <count group_id="O3" value="621"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>live-born infants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.51</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Generalized estimating equations with logistic link to account for multiple pregnancies and multiple births</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.86</p_value>
            <method>Regression, Logistic</method>
            <method_desc>generalized estimating equations with logistic link to account for multiple pregnancies and multiple births</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length Among Infants Born to Female Participants Taking Study Drug</title>
        <description>The slope of the linear model of the growth of infants (length) during the entirety of follow-up. The length of the infant was measured as a z-score, in terms of standard deviations from the age and gender specific median using the World Health Organization growth curve, accounting for skewness. The slope, representing the change over time of the z-score, was calculated using all available z-scores over 12 months and regressing against study month.</description>
        <time_frame>up to 12 months</time_frame>
        <population>Infants born to women taking study drug during follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir Disoproxil Fumarate (TDF)</title>
            <description>Tenofovir Disoproxil Fumarate (TDF): TDF 300 mg tablet, once daily + Placebo FTC/TDF orally, once daily.</description>
          </group>
          <group group_id="O2">
            <title>Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)</title>
            <description>Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF): FTC/TDF - 200 mg tablet, once daily + Placebo TDF orally, once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo TDF + Placebo FTC/TDF orally, once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Length Among Infants Born to Female Participants Taking Study Drug</title>
          <description>The slope of the linear model of the growth of infants (length) during the entirety of follow-up. The length of the infant was measured as a z-score, in terms of standard deviations from the age and gender specific median using the World Health Organization growth curve, accounting for skewness. The slope, representing the change over time of the z-score, was calculated using all available z-scores over 12 months and regressing against study month.</description>
          <population>Infants born to women taking study drug during follow-up</population>
          <units>z-score difference per study month</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.006"/>
                    <measurement group_id="O2" value="0.036"/>
                    <measurement group_id="O3" value="-0.033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.42</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>linear mixed-effects model</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.08</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Linear mixed-effects model</method_desc>
            <param_type>Slope Difference over time</param_type>
            <param_value>0.07</param_value>
            <estimate_desc>Placebo arm is the reference group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weight Among Infants Born to Female Participants Taking Study Drug</title>
        <description>The slope of the linear model of the growth of infants (weight) during the entirety of follow-up. The weight of the infant was measured as a z-score, in terms of standard deviations from the age and gender specific median using the World Health Organization growth curve, accounting for skewness. The slope, representing the change over time of the z-score, was calculated using all available z-scores over 12 months and regressing against study month.</description>
        <time_frame>up to 12 months</time_frame>
        <population>Infants born to women taking study drug during follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir Disoproxil Fumarate (TDF)</title>
            <description>Tenofovir Disoproxil Fumarate (TDF): TDF 300 mg tablet, once daily + Placebo FTC/TDF orally, once daily.</description>
          </group>
          <group group_id="O2">
            <title>Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)</title>
            <description>Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF): FTC/TDF - 200 mg tablet, once daily + Placebo TDF orally, once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo TDF + Placebo FTC/TDF orally, once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Weight Among Infants Born to Female Participants Taking Study Drug</title>
          <description>The slope of the linear model of the growth of infants (weight) during the entirety of follow-up. The weight of the infant was measured as a z-score, in terms of standard deviations from the age and gender specific median using the World Health Organization growth curve, accounting for skewness. The slope, representing the change over time of the z-score, was calculated using all available z-scores over 12 months and regressing against study month.</description>
          <population>Infants born to women taking study drug during follow-up</population>
          <units>z-score difference per study month</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.021"/>
                    <measurement group_id="O2" value="0.009"/>
                    <measurement group_id="O3" value="-0.056"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Linear mixed effects model</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Linear mixed effects model</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Head Circumference Among Infants Born to Female Participants Taking Study Drug</title>
        <description>The slope of the linear model of the growth of infants (head circumference) during the entirety of follow-up. The head circumference of the infant was measured as a z-score, in terms of standard deviations from the age and gender specific median using the World Health Organization growth curve, accounting for skewness. The slope, representing the change over time of the z-score, was calculated using all available z-scores over 12 months and regressing against study month.</description>
        <time_frame>up to 12 months</time_frame>
        <population>Infants born to women taking study drug during follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir Disoproxil Fumarate (TDF)</title>
            <description>Tenofovir Disoproxil Fumarate (TDF): TDF 300 mg tablet, once daily + Placebo FTC/TDF orally, once daily.</description>
          </group>
          <group group_id="O2">
            <title>Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)</title>
            <description>Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF): FTC/TDF - 200 mg tablet, once daily + Placebo TDF orally, once daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo TDF + Placebo FTC/TDF orally, once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Head Circumference Among Infants Born to Female Participants Taking Study Drug</title>
          <description>The slope of the linear model of the growth of infants (head circumference) during the entirety of follow-up. The head circumference of the infant was measured as a z-score, in terms of standard deviations from the age and gender specific median using the World Health Organization growth curve, accounting for skewness. The slope, representing the change over time of the z-score, was calculated using all available z-scores over 12 months and regressing against study month.</description>
          <population>Infants born to women taking study drug during follow-up</population>
          <units>z-score difference per study month</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.057"/>
                    <measurement group_id="O2" value="-0.005"/>
                    <measurement group_id="O3" value="-0.079"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.35</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Linear mixed effects model</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Linear mixed effects model</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 36 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tenofovir Disoproxil Fumarate (TDF)</title>
          <description>TDF 300 mg tablet, once daily + Placebo FTC/TDF orally, once daily.</description>
        </group>
        <group group_id="E2">
          <title>Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)</title>
          <description>FTC/TDF - 200 mg tablet, once daily + Placebo TDF orally, once daily</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo TDF &amp; Placebo FTC/TDF, 1 tablet each daily.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="118" subjects_at_risk="1584"/>
                <counts group_id="E2" subjects_affected="115" subjects_at_risk="1579"/>
                <counts group_id="E3" subjects_affected="118" subjects_at_risk="1584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>ANKYLOGLOSSIA CONGENITAL</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>EXOMPHALOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1579"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>HYPOSPADIAS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>POLYDACTYLY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>SYNDACTYLY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>VENTRICULAR SEPTAL DEFECT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>BLINDNESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>CATARACT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1584"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>OPTIC NEUROPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL HERNIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1584"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1579"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>ACUTE ABDOMEN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>DIARRHOEA HAEMORRHAGIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1584"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>DIVERTICULUM INTESTINAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>FOOD POISONING</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>HAEMATEMESIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1584"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1579"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>PEPTIC ULCER</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1584"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1579"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>PROCTITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1579"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>TOOTH DEVELOPMENT DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>UMBILICAL HERNIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>VOLVULUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>INFLUENZA LIKE ILLNESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>ALLERGY TO ARTHROPOD STING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>ANAPHYLACTIC REACTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ACUTE HIV INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>ANAL INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>BREAST ABSCESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>BRONCHOPNEUMONIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>BRUCELLOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>CEREBRAL MALARIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>CERVICITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="566"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>DYSENTERY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>FEBRILE INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1584"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1579"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1584"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1579"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS SHIGELLA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>HORDEOLUM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>LOBAR PNEUMONIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>LOWER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>LUNG ABSCESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>MALARIA</sub_title>
                <counts group_id="E1" events="31" subjects_affected="28" subjects_at_risk="1584"/>
                <counts group_id="E2" events="30" subjects_affected="28" subjects_at_risk="1579"/>
                <counts group_id="E3" events="40" subjects_affected="37" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>ORCHITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1584"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>PELVIC ABSCESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>PELVIC INFLAMMATORY DISEASE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="598"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="566"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1579"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE WOUND INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>PULMONARY TUBERCULOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1579"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1579"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>SALPINGITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="566"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>TYPHOID FEVER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1584"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1579"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ALCOHOL POISONING</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>CATARACT TRAUMATIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>CHEMICAL EYE INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>CHEST INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>CLAVICLE FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>DRUG TOXICITY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>ELECTROCUTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>FEMUR FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>FIBULA FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>GUN SHOT WOUND</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>HEAD INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1579"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>HUMERUS FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>INDUCED ABORTION HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="566"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>INJURY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>LOWER LIMB FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>POISONING</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>ROAD TRAFFIC ACCIDENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1584"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1579"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>SCIATIC NERVE INJURY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>SOFT TISSUE INJURY</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1584"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1579"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>STRUCK BY LIGHTNING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>TENDON RUPTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>THERMAL BURN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>TIBIA FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1584"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1579"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>ASPARTATE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1584"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1579"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>BLOOD BILIRUBIN INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>BLOOD GLUCOSE DECREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>BLOOD PHOSPHORUS DECREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>HAEMOGLOBIN DECREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1584"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1579"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>NEUTROPHIL COUNT DECREASED</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="1584"/>
                <counts group_id="E2" events="20" subjects_affected="18" subjects_at_risk="1579"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>PLATELET COUNT DECREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1584"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1579"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>WHITE BLOOD CELL COUNT DECREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>DIABETIC COMPLICATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>FRACTURE MALUNION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC PROTRUSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>CERVIX CARCINOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="566"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL CARCINOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>UTERINE LEIOMYOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="566"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="621"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CEREBRAL INFARCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>CONVULSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>LOSS OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>NEUROPATHY PERIPHERAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>ABORTION SPONTANEOUS</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="598"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="566"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>ANTEPARTUM HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="566"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>NORMAL DELIVERY</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="598"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="566"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>PERINEAL LACERATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="566"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>POSTPARTUM HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="566"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>PREMATURE LABOUR</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="566"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>PROLONGED LABOUR</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="566"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="621"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE PSYCHOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>COMPLETED SUICIDE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>MAJOR DEPRESSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>SCHIZOPHRENIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>SUICIDE ATTEMPT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1584"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1579"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE PRERENAL FAILURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>BENIGN PROSTATIC HYPERPLASIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="986"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1013"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="963"/>
              </event>
              <event>
                <sub_title>CERVIX DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="566"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>FALLOPIAN TUBE CYST</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="566"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>METRORRHAGIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="598"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="566"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>OVARIAN CYST</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="598"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="566"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="621"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1579"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>PLEURISY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>SCAR PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>VICTIM OF CRIME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>COLOSTOMY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1584"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1579"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1584"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1579"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1584"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1306" subjects_at_risk="1584"/>
                <counts group_id="E2" subjects_affected="1316" subjects_at_risk="1579"/>
                <counts group_id="E3" subjects_affected="1297" subjects_at_risk="1584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="56" subjects_affected="48" subjects_at_risk="1584"/>
                <counts group_id="E2" events="39" subjects_affected="37" subjects_at_risk="1579"/>
                <counts group_id="E3" events="41" subjects_affected="39" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" events="22" subjects_affected="20" subjects_at_risk="1584"/>
                <counts group_id="E2" events="31" subjects_affected="28" subjects_at_risk="1579"/>
                <counts group_id="E3" events="28" subjects_affected="24" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="1584"/>
                <counts group_id="E2" events="23" subjects_affected="22" subjects_at_risk="1579"/>
                <counts group_id="E3" events="24" subjects_affected="24" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>DIARRHOEA HAEMORRHAGIC</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="1584"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="1579"/>
                <counts group_id="E3" events="17" subjects_affected="15" subjects_at_risk="1584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>MALARIA</sub_title>
                <counts group_id="E1" events="371" subjects_affected="290" subjects_at_risk="1584"/>
                <counts group_id="E2" events="356" subjects_affected="267" subjects_at_risk="1579"/>
                <counts group_id="E3" events="352" subjects_affected="280" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="147" subjects_affected="125" subjects_at_risk="1584"/>
                <counts group_id="E2" events="189" subjects_affected="159" subjects_at_risk="1579"/>
                <counts group_id="E3" events="169" subjects_affected="142" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="117" subjects_affected="108" subjects_at_risk="1584"/>
                <counts group_id="E2" events="107" subjects_affected="91" subjects_at_risk="1579"/>
                <counts group_id="E3" events="133" subjects_affected="114" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="121" subjects_affected="105" subjects_at_risk="1584"/>
                <counts group_id="E2" events="96" subjects_affected="86" subjects_at_risk="1579"/>
                <counts group_id="E3" events="122" subjects_affected="103" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>PELVIC INFLAMMATORY DISEASE</sub_title>
                <counts group_id="E1" events="71" subjects_affected="59" subjects_at_risk="598"/>
                <counts group_id="E2" events="55" subjects_affected="48" subjects_at_risk="566"/>
                <counts group_id="E3" events="62" subjects_affected="55" subjects_at_risk="621"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" events="36" subjects_affected="33" subjects_at_risk="1584"/>
                <counts group_id="E2" events="34" subjects_affected="32" subjects_at_risk="1579"/>
                <counts group_id="E3" events="32" subjects_affected="30" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>TYPHOID FEVER</sub_title>
                <counts group_id="E1" events="39" subjects_affected="32" subjects_at_risk="1584"/>
                <counts group_id="E2" events="31" subjects_affected="28" subjects_at_risk="1579"/>
                <counts group_id="E3" events="24" subjects_affected="23" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>SYPHILIS</sub_title>
                <counts group_id="E1" events="30" subjects_affected="28" subjects_at_risk="1584"/>
                <counts group_id="E2" events="31" subjects_affected="27" subjects_at_risk="1579"/>
                <counts group_id="E3" events="24" subjects_affected="23" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" events="27" subjects_affected="26" subjects_at_risk="1584"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="1579"/>
                <counts group_id="E3" events="27" subjects_affected="26" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>URETHRITIS</sub_title>
                <counts group_id="E1" events="33" subjects_affected="26" subjects_at_risk="1584"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="1579"/>
                <counts group_id="E3" events="22" subjects_affected="20" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="1584"/>
                <counts group_id="E2" events="19" subjects_affected="17" subjects_at_risk="1579"/>
                <counts group_id="E3" events="23" subjects_affected="21" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="1584"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="1579"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="1584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>SOFT TISSUE INJURY</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="1584"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="1579"/>
                <counts group_id="E3" events="17" subjects_affected="16" subjects_at_risk="1584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>NEUTROPHIL COUNT DECREASED</sub_title>
                <counts group_id="E1" events="1109" subjects_affected="598" subjects_at_risk="1584"/>
                <counts group_id="E2" events="1322" subjects_affected="686" subjects_at_risk="1579"/>
                <counts group_id="E3" events="1076" subjects_affected="577" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>BLOOD PHOSPHORUS DECREASED</sub_title>
                <counts group_id="E1" events="763" subjects_affected="440" subjects_at_risk="1584"/>
                <counts group_id="E2" events="785" subjects_affected="460" subjects_at_risk="1579"/>
                <counts group_id="E3" events="787" subjects_affected="473" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>HAEMOGLOBIN DECREASED</sub_title>
                <counts group_id="E1" events="384" subjects_affected="259" subjects_at_risk="1584"/>
                <counts group_id="E2" events="335" subjects_affected="230" subjects_at_risk="1579"/>
                <counts group_id="E3" events="331" subjects_affected="231" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>PLATELET COUNT DECREASED</sub_title>
                <counts group_id="E1" events="306" subjects_affected="190" subjects_at_risk="1584"/>
                <counts group_id="E2" events="305" subjects_affected="188" subjects_at_risk="1579"/>
                <counts group_id="E3" events="298" subjects_affected="177" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>BLOOD BICARBONATE DECREASED</sub_title>
                <counts group_id="E1" events="142" subjects_affected="123" subjects_at_risk="1584"/>
                <counts group_id="E2" events="130" subjects_affected="118" subjects_at_risk="1579"/>
                <counts group_id="E3" events="148" subjects_affected="135" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>ASPARTATE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="138" subjects_affected="93" subjects_at_risk="1584"/>
                <counts group_id="E2" events="146" subjects_affected="103" subjects_at_risk="1579"/>
                <counts group_id="E3" events="124" subjects_affected="96" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>BLOOD CREATININE INCREASED</sub_title>
                <counts group_id="E1" events="99" subjects_affected="76" subjects_at_risk="1584"/>
                <counts group_id="E2" events="126" subjects_affected="107" subjects_at_risk="1579"/>
                <counts group_id="E3" events="108" subjects_affected="86" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="103" subjects_affected="90" subjects_at_risk="1584"/>
                <counts group_id="E2" events="104" subjects_affected="87" subjects_at_risk="1579"/>
                <counts group_id="E3" events="85" subjects_affected="73" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>WHITE BLOOD CELL COUNT DECREASED</sub_title>
                <counts group_id="E1" events="59" subjects_affected="50" subjects_at_risk="1584"/>
                <counts group_id="E2" events="93" subjects_affected="71" subjects_at_risk="1579"/>
                <counts group_id="E3" events="83" subjects_affected="64" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>BLOOD BILIRUBIN INCREASED</sub_title>
                <counts group_id="E1" events="82" subjects_affected="56" subjects_at_risk="1584"/>
                <counts group_id="E2" events="64" subjects_affected="49" subjects_at_risk="1579"/>
                <counts group_id="E3" events="88" subjects_affected="63" subjects_at_risk="1584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>ABORTION SPONTANEOUS</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="598"/>
                <counts group_id="E2" events="20" subjects_affected="19" subjects_at_risk="566"/>
                <counts group_id="E3" events="17" subjects_affected="17" subjects_at_risk="621"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>PROTEINURIA</sub_title>
                <counts group_id="E1" events="47" subjects_affected="40" subjects_at_risk="1584"/>
                <counts group_id="E2" events="46" subjects_affected="36" subjects_at_risk="1579"/>
                <counts group_id="E3" events="43" subjects_affected="34" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>URETHRAL DISCHARGE</sub_title>
                <counts group_id="E1" events="20" subjects_affected="17" subjects_at_risk="1584"/>
                <counts group_id="E2" events="23" subjects_affected="21" subjects_at_risk="1579"/>
                <counts group_id="E3" events="22" subjects_affected="18" subjects_at_risk="1584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>GENITAL ULCERATION</sub_title>
                <counts group_id="E1" events="29" subjects_affected="26" subjects_at_risk="1584"/>
                <counts group_id="E2" events="48" subjects_affected="35" subjects_at_risk="1579"/>
                <counts group_id="E3" events="38" subjects_affected="34" subjects_at_risk="1584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>PHARYNGOLARYNGEAL PAIN</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="1584"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="1579"/>
                <counts group_id="E3" events="28" subjects_affected="27" subjects_at_risk="1584"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="25" subjects_affected="22" subjects_at_risk="1584"/>
                <counts group_id="E2" events="21" subjects_affected="20" subjects_at_risk="1579"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="1584"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="1584"/>
                <counts group_id="E2" events="18" subjects_affected="14" subjects_at_risk="1579"/>
                <counts group_id="E3" events="42" subjects_affected="30" subjects_at_risk="1584"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Connie Celum</name_or_title>
      <organization>University of Washington</organization>
      <phone>206-520-3824</phone>
      <email>ccelum@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

